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The development of an MRM assay for the measurements of six inﬂammatory markers
is  presented. We  report a robust and sensitive quantitative assay with a relative standard
deviation of <15% that accounts for the entire sample processing. The assay has a dynamic
range with 4 orders of magnitude and the LOQs are in the attomolar range. We  used plasma
from  Huntington’s disease gene carriers and healthy controls to compare our MRM method
with antibody based methods. Importantly, we found a good agreement between assays
for  the measurement of C-reactive protein, in contrast to complement component 3 andKeywords:
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© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). 
MRM approach provides absolute quantiﬁcation of the ana-
lyte concentration. Mass spectrometry based quantitative
Open access under CC BY-NC-ND license.1.  Introduction
The major mass spectrometry (MS) based protein analysis
principles that have progressed over the years can be divided
into: (1) global expression analysis, analyzing thousands of
proteins and sequencing minute amounts of sample [1–3], and
(2) targeted analysis targeting a speciﬁc and smaller set of pro-
teins measured in dedicated assays such as multiple reaction
monitoring (MRM)  assays. In recent years, MRM has become
∗ Corresponding author at: Clinical Protein Science & Imaging, Departm
neering, Lund University, BMC D13, SE-221 84 Lund, Sweden. Tel.: +46 4
E-mail address: melinda.rezeli@elmat.lth.se (M. Rezeli).
http://dx.doi.org/10.1016/j.euprot.2014.02.003
2212-9685 © 2014 The Authors. Published by Elsevier B.V. on behalf ofvery popular due to its generic concept and the ability to per-
form multiplex quantiﬁcation [4,5].
MRM is the mass spectrometric scan type with the high-
est duty cycle that can monitor one or more  speciﬁc ion
transition(s) at high sensitivity. When it is combined with
appropriate stable isotope-labeled internal standards, theent of Measurement Technology and Industrial Electrical Engi-
6 222 3721; fax: +46 46 222 4527.
assays for small molecules have been used in both research
and clinical laboratories and also in the pharmaceutical
 European Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
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ndustry for years, and, more  recently, the technique has been
pplied to protein quantiﬁcation [6–9]. Although MS provides
equence information of the targets, i.e., molecular speciﬁcity,
nd has a potential to discriminate and measure different
rotein variants simultaneously, MS  based protein quantiﬁca-
ion has not yet been adopted by clinical laboratories, mostly
ue to sensitivity issues, long analysis time and consider-
ble costs of the analyses in comparison with immunoassays.
dditionally, there is a lack of biomarkers measurable by MS-
ased assays that can improve the clinical outcome [10–12].
everal approaches have been presented to reduce sample
omplexity, thereby increasing sensitivity. The most promis-
ng techniques involve immune-enrichment at protein [13] or
eptide level [9,14] prior the MS  readout allowing detection
nd quantiﬁcation of targets as low as pg/mL concentration
n blood plasma. The robustness of the MRM  technology has
lso been reported in inter-laboratory studies presenting high
eproducibility that could fulﬁll the requirements for clinical
pplications [15,16]. The multiplexing ability of the technique
as enormous advantage in contrast to immunoassays. Par-
llel measurement of different protein targets in one assay
educes both the net analysis time and cost, and decreases
he measurement error. Recent technological advances make
RM  protein assays a convincing alternative to the classical
mmune-based methods [17].
The complement system is part of the innate immune
ystem, consisting of a number of circulating and membrane-
ssociated proteins. The main function of the complement
ystem is the protection of the host body against pathogens
ut a number of studies have suggested its involvement in
he development of neurodegenerative disorders, such as
lzheimer’s and Parkinson’s diseases and multiple sclerosis,
s well as in other diseases, such as asthma and arthritis
18,19]. There is increasing evidence that complement acti-
ation has a role in the pathogenesis of neurodegenerative
isorders, including Huntington’s disease (HD) [20,21]. Com-
lement components have been reported to be increased with
isease progression in HD plasma [22] in accordance with
ncreased complement activation in HD brains [23], however,
o changes in plasma levels of complement components have
lso been reported [24].
In the present paper we  report on quantitative mass
pectrometry assay development for the measurement of
omplement components and C-reactive protein. We have
nvestigated the analytical performance of a nanoLC–MRM-MS
latform by using the stable isotope dilution strategy. Markers
nvolved in innate immunity were measured in plasma in a
ohort consisting of HD gene carriers and controls.
.  Experimental
.1.  Materials
ater (Chromasolv® Plus for HPLC), formic acid (reagent
rade ≥ 95%), dithiothreitol and iodoacetamide were pur-
hased from Sigma–Aldrich (Steinheim, Germany); acetoni-
rile (Hypergrade for LC–MS) was from Merck (Darmstadt,
ermany). Sequence grade trypsin was purchased from
romega (Madison, WI). Light and heavy sequences of the 3 ( 2 0 1 4 ) 68–75 69
target peptides with purity higher than 97% (AQUA Quant-
Pro quality) were purchased from Thermo Fischer Scientiﬁc
(Ulm, Germany). The C-terminal arginine or lysine was labeled
with 13C and 15N in the heavy forms, providing an increased
nominal mass of 10 and 8 Da, respectively.
2.2.  Clinical  materials
In the current study we used samples from 30 healthy
controls, 30 premanifest HD and 30 early HD subjects. Non-
fasting plasma samples were obtained from control subjects
and genetically diagnosed HD patients in the morning and
processed as previously described [25]. Participants were
recruited through the HD Multidisciplinary Clinic of the
National Hospital for Neurology and Neurosurgery, London,
UK. Premanifest carriers of the gene were required to have a
disease burden score greater than 250 at recruitment, approx-
imating to less than 15 years to estimated onset, and a total
motor score (TMS) of ﬁve or less in the Uniﬁed Huntington’s
Disease Rating Scale (UHDRS) motor assessment [26]. Partic-
ipants in the control group were matched for age and sex to
the combined premanifest and early HD groups. The study was
conducted in accordance with the declaration of Helsinki and
was approved by local ethics review boards; all subjects gave
informed written consent.
2.3.  Sample  preparation  for  mass  spectrometric
analysis
The seven most abundant proteins were depleted in 10 L
of plasma in each case by using Multiple Afﬁnity Removal
Spin Cartridge, Human-7 (Agilent Technologies, Santa Clara,
CA). Following speed vacuum centrifugation the two ﬂow-
through fractions from each depleted plasma sample were
combined and dissolved in 200 L of 50 mM ammonium bicar-
bonte buffer containing 8 M urea, pH 7.8. The proteins were
reduced with 10 mM dithiothreitol (60 min, 37 ◦C) and alkyl-
ated with 50 mM iodoacetamide (30 min, at room temperature
in dark). The excess of the reagents was removed by buffer
exchange with 50 mM ammonium bicarbonate buffer, pH 7.8
using a 10 kDa cut-off spin ﬁlter (Millipore, Billerica, MA). The
sample volume for the digestion was adjusted to 200 L, the
proteins were digested with sequence grade trypsin (ca. 1:100
enzyme:protein ratio) for 18 h at 37 ◦C and then the digestion
was stopped by the addition of 10 L of 10% formic acid. The
digested plasma samples were dried by speed vacuum cen-
trifugation and re-dissolved in 0.1% formic acid corresponding
to 100 times dilution of the original plasma. Samples were
then spiked with a mixture of heavy isotope-labeled peptide
standards (12.5 fmol/L ﬁnal concentration for each peptide)
and analyzed by nanoLC–MRM-MS.
2.4.  Quantitative  LC–MS/MS  analysis
Isotopically labeled peptides for optimization of the assay
were mixed and diluted with 5% ACN at a concentration
of 25 fmol/L for each synthetic peptide. The mixture was
analyzed by nanoLC–MS/MS using a TSQ Vantage triple
quadrupole mass spectrometer equipped with an Easy n-LC
II pump (Thermo Scientiﬁc, Waltham, MA). 2 L of samples
o m i c70  e u  p a o p e n p r o t e 
were injected onto an Easy C18-A1 pre-column (Thermo Sci-
entiﬁc, Waltham, MA), and following on-line desalting and
trapping at a pressure of 280 bar the peptides were separated
on a 75 m × 150 mm fused silica column packed with ReproSil
C18 (3 m,  120 A˚ from Dr. Maisch GmbH, Germany). Separa-
tions were performed in a 25-min linear gradient from 10 to
35% acetonitrile containing 0.1% formic acid at the ﬂow rate
of 300 nL/min. The MS analysis was conducted in positive ion
mode at 1750 V applied spray voltage. The transfer capillary
temperature was 270 ◦C and tuned S-lens value was used. SRM
transitions were acquired in Q1 and Q3 operated at unit res-
olution (0.7 FWHM), the collision gas pressure in Q2 was set
to 1.2 mTorr. Scheduled method was used for data acquisition
with 4 min  time windows and the cycle time was set to 1.5 s,
while the maximum number of consecutive transitions was
50.The SRM assay optimization was done with the aid of Sky-
line v1.2 software (MacCoss Lab). Primarily, high numbers of
transitions, all possible b- and y-ion series, were chosen for
Table 1 – Proteotypic peptide sequences and selected SRM tran
Accession no. Protein Peptide seque
P01024 Complement C3 (C3) TGLQEVEVK
TGLQEVEVK 
P00751 Complement
fac-
tor
B
(CFB)
EELLPAQDIK 
EELLPAQDIK 
P08603 Complement
fac-
tor
H
(CFH)
SPDVINGSPIS
SPDVINGSPIS
P01031 Complement
C5
(C5)
IDTQDIEASH
IDTQDIEASH
P02748 Complement
C9
(C9)
TEHYEEQIEA
TEHYEEQIEA
P02741 C-
reactive
pro-
tein
(CRP)
ESDTSYVSLK
ESDTSYVSLK
a The listed transitions were selected in the ﬁnal assay as best transitions s 3 ( 2 0 1 4 ) 68–75
each peptide at both 2+ and 3+ charge states. The best 3–6
transitions were selected for further analysis and three transi-
tions, producing the most abundant signals without observed
interferences in a real background matrix, were utilized for
ﬁnal quantiﬁcation. Collision energies (CE) were optimized for
each transition. The energy was ramped around the predicted
value in 5 steps on both sides with 1 V increments [27].
For the sample analysis the same chromatographic con-
ditions were used as described previously for the assay
development and the optimized parameters were used during
the MS/MS data acquisition. Identical SRM parameters were
used for the heavy and natural forms of each peptide, while
taking into account the Q1/Q3 mass differences due to the sta-
ble isotope labeling. Table 1 presents the protein and signal
peptide sequences in our assay together with the monitored
transitions.To control the instrument performance a QC sample that
consist of a mixture of heavy and light synthetic peptides
at a concentration of 12.5 and 5 fmol/L, respectively, was
sitions for the six analyzed plasma proteins.
nce Q1 Q3a CE
501.8 (2+) 731.4  (y61+) 18
603.3 (y51+) 18
474.3 (y41+) 20
505.8
(2+)
739.4  (y61+) 18
611.3 (y51+) 18
482.3 (y41+) 20
578.3
(2+)
897.5  (y81+) 18
784.5 (y71+) 18
671.4 (y61+) 18
582.3
(2+)
905.6  (y81+) 18
792.5 (y71+) 18
679.4 (y61+) 18
QK 671.4
(2+)
943.5 (y91+) 26
830.4 (y81+) 26
716.4 (y71+) 26
QK 675.4
(2+)
951.5  (y91+) 26
838.4 (y81+) 26
724.4 (y71+) 26
YR 483.2
(3+)
990.5 (y81+) 20
633.3 (y51+) 20
562.3 (y41+) 20
YR 486.6
(3+)
1000.5  (y81+) 20
643.3 (y51+) 20
572.3 (y41+) 20
FK 508.6
(3+)
607.3  (y51+) 19
494.3 (y41+) 19
365.2 (y31+) 21
FK 511.2
(3+)
615.4  (y51+) 19
502.3 (y41+) 19
373.2 (y31+) 21
564.8
(2+)
696.4 (y61+) 20
609.4 (y51+) 18
446.3 (y41+) 20
568.8
(2+)
704.4  (y61+) 20
617.4 (y51+) 18
454.3 (y41+) 20
 for quantiﬁcation.
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ntegrated into the running sequence. After the analysis of 8
atient samples one QC sample was injected, which was fol-
owed by three blank runs. These QC runs were evaluated and
he variations of the absolute and relative peak areas were
onitored over the entire study.
.5.  Data  analysisll raw data generated on the triple quadrupole mass spec-
rometer were imported to Skyline v1.2 software for data
nalysis. Quantiﬁcation was based on the ratio of correspond-
ng light and heavy peak areas. The peak integration was done
ig. 1 – Linearity of the MRM  assay determined by using heavy la
arious concentrations (0.005–50 fmol/L). The measured levels o
hereas the LOQ (CV < 20%) is indicated with arrow. 3 ( 2 0 1 4 ) 68–75 71
automatically by the software, using Savitzky–Golay smooth-
ing, and all the data were manually inspected to conﬁrm the
correct peak detection. Further statistical analysis was done
using Microsoft Excel, R and Matlab v7.11 (Mathworks, Natick,
MA).
3.  Results3.1.  Assay  development
For the build of the multiplex protein assay we selected one
representative, unique proteotypic peptide for each target
beled IS peptides spiked into pooled plasma digest at
f the endogenous peptides are shown as blue diamonds,
o m i c72  e u  p a o p e n p r o t e 
protein and one precursor ion for each peptide. With the aid of
Skyline software we selected the best transitions, preferably
y-ions with higher mass to charge values free from matrix
interferences and optimized the collision energies as well,
and the three best transitions were used for quantiﬁcation
(Table 1). We  also investigated the linearity within a concen-
tration range of 0.2–200 fmol/L in buffer solution and in real
matrix. All signal responses were linear in the tested concen-
tration range, represented by regression coefﬁcients higher
than 0.98. The limit of quantiﬁcation (LOQ) was determined for
each target peptide by creating and analyzing a dilution series
of pooled plasma digest spiked with different amount of heavy
internal standards ranging from 0.005 fmol/L to 50 fmol/L
in ﬁve replicates. The LOQ of these peptides in blood plasma
was estimated as the lowest concentration measured with CV
<20% and was found to be in the attomolar range (10–100 atto-
moles on column), see Fig. 1.
3.2.  Reproducibility  of  the  assay
Prior to the clinical sample analysis we evaluated the repro-
ducibility of the complete preparation workﬂow that includes
depletion, digestion and spiking with heavy standards as
well. Additionally, depletion spin cartridges from two differ-
ent batches were compared and we  could not ﬁnd signiﬁcant
differences in their performance. Fig. 2 shows the compar-
ison of the two cartridges based on the measurements of
three biological replicates on each depletion cartridge. We
obtained somewhat higher variations when using the ﬁrst
batch, but the coefﬁcient of variation (CV) values were less
than 20% for each target protein. The preparations of the clin-
ical samples were performed on different days due to the high
number of samples; therefore, we used a control plasma sam-
ple from a healthy volunteer, which was treated in the same
way as clinical patient samples on each day. These processing
controls were used for the evaluation of the reproducibility
of the complete sample processing workﬂow. The variation
of the spiking with heavy labeled internal standards was
also evaluated. The CV of the total sample processing, which
was calculated based on the triplicate measurements of four
Fig. 2 – Comparison of the performance of two different
depletion cartridges. s 3 ( 2 0 1 4 ) 68–75
sample processing controls was equal or less than 15% for the
6 target peptides, whereas the relative standard deviation in
testing the sample spiking with heavy standards was ≤10%.
Furthermore, ≈20% of the total samples was run in trip-
licates in order to evaluate the variation of the assay. The
variation of the MRM measurement due to the isotopically
labeled internal standards was very low, because the quan-
tiﬁcation is based on the endogenous signal relative to the
internal standard signal. 40% of the triplicate measurements
had relative standard deviation (RSD) equal or less than 2%,
and in 75% of the measurements the RSD is equal or less than
5%, as it is displayed in Fig. 3.
The patient samples were analyzed randomly and quality
control samples (mixture of light and heavy synthetic pep-
tides) were run regularly using the same method to control
the instrument performance. The variation of the calculated
relative peak intensities in the control samples was below
5%, while the absolute signal intensities varied with 25% or
less during the analysis of the complete patient sample set.
This observation supports the beneﬁt of using isotopically
labeled internal standards. We  observed similar values (≤25%)
when the heavy labeled internal standard signal intensities in
the entire set of analyzed samples were compared, while the
retention time variation was less than 1%.
3.3.  Analysis  of  Huntington’s  disease  patient  samples
We have analyzed EDTA plasma pooled from 16 individ-
uals each and 90 individual patient samples from early and
premanifest Huntington’s disease patients and age matched
control donors (Suppl. Table 1). The analysis of the indi-
vidual samples conﬁrmed the observations made by the
investigation of the pooled samples, we recognized the same
tendencies in protein levels in-between the 3 sample groups
(Fig. 4).
Some of the markers were measured simultaneously
with antibody-based assays and the results of the different
methods were compared. Interestingly, we  could ﬁnd good
agreement between the assays only in the measurement of
C-reactive protein (CRP) but not in complement factor H (CFH)
and complement component 3 (C3). The correlation coefﬁcient
Fig. 3 – Illustration of the technical reproducibility of the
MRM assay.
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as 0.925 for CRP, 0.442 for CFH and −0.053 for complement
3 (Suppl. Fig. 1)..  Discussion
he targets of the assay herein described are identical
o the assay we  reported earlier [28]. However, due to
ig. 4 – Box-plot illustration of the levels of the six inﬂammatory
epresents each individual sample and the levels of the pooled s 3 ( 2 0 1 4 ) 68–75 73
different instrumentation the assay parameters, such as tran-
sition selection, collision energy, and cycle time, were newly
optimized. The triple quadrupole instrument allows us to
monitor more  transitions without losing the appropriate
amount of data points across the peak and in addition, pro-
vides wider dynamic range and improved sensitivity. The
reproducibility of the MRM assay performed on the TSQ Van-
tage instrument was considerably better than that in the
 markers measured in the three patient groups. A circle
amples are illustrated as squares.
74  e u  p a o p e n p r o t e o m i c
Fig. 5 – Box-plot illustration of the reproducibility of the
r
proteins in body ﬂuids using targeted proteomics. Scienceassay based on triplicate measurements.
previous assay executed on a linear ion trap instrument.
The precision of the assay was dependent on protein con-
centration and on the concentration of the spiked internal
standard. The relative standard deviation of the triplicate
measurements was much lower when the concentration ratio
of the endogenous compound and the corresponding internal
standard was close to 1, as illustrated in Fig. 5. This obser-
vation agrees well with the ﬁnding of Borchers’ group [29].
The best precision was achieved by the measurements of C3
and CFB, where the average endogenous/standard ratios were
kept at 2.3 and 0.5, respectively, while the poorest relative
standard deviations were measured for CFH and CRP with
average endogenous/standard ratios of 0.08 and 0.04, respec-
tively.
The removal of the most abundant proteins from plasma
increased the preparation time and moderate and low abun-
dant proteins might be lost in this step due to non-speciﬁc
binding. However, depletion could contribute to protecting
the chromatographic system from overload, minimizing the
matrix interferences and improve the analytical reproducibil-
ity. Our previous results showed that the depletion step did not
signiﬁcantly increase the variation of the sample preparation
but in addition improved the measurement precision [30].
Although increasing number of studies have demonstrated
the role of the complement system in neurodegenerative
diseases and reported up- and down-regulated complement
system members based on comparative proteomics analysis
of different patient groups [22,23], we  were not able to jus-
tify these ﬁndings by the investigation of two different subject
cohorts [24]. These contradictory results may be attributed
to different patient material handling, heterogeneity of the
patient cohort or the various measurement procedures. Paral-
lel to the mass spectrometry based quantiﬁcation additional
inﬂammatory markers were measured in the same sample
cohort using antibody-based assays (Luminex assays). None
of the examined markers showed correlation with disease
progression as it was reported in our recent publication [24].
Three of the markers were measured with both antibody and
MRM  assays in this study but interestingly, only the CRP values
showed good correlation between the two techniques. CRP is a
relatively small molecule, in comparison with C3 and CFH that s 3 ( 2 0 1 4 ) 68–75
have many  different epitopes, against which antibodies are
available with various speciﬁcities. A possible explanation for
the poor correlation in-between the two quantiﬁcation tech-
niques may be that the Luminex assay detects different forms
of the protein, or has different afﬁnity to different forms than
the MRM assay.
5.  Conclusions
In the present paper we  reported on a quantitative mass
spectrometry assay developed for the measurement of com-
plement components and C-reactive protein. We presented
a highly reproducible nanoLC–MRM-MS platform that allows
absolute quantiﬁcation of 6 target proteins using the stable
isotope dilution strategy. The assay had a dynamic range with
at least 4 orders of magnitude and the LOQs of the various tar-
gets were in the attomolar range. The assay was successfully
utilized for the analysis of a HD patient cohort.
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